Pharmaceutical company Almirall, a CataloniaBio & HealthTech member, and biotechnology firm Tyris Therapeutics have announced a new alliance to develop non-viral gene therapies to treat minority dermatology diseases.

Tyris has cutting-edge proprietary technology and will be in charge of generating the drugs through to clinical trials. The Spanish biotech company is funded by Columbus Venture Partners.

The deal is part of Almirall’s strategy to offer innovative medical solutions for skin health.

More information

Subscribe to Directory
Write an Article

Recent News

Exposure to Heat and Cold During Pregnan...

The research team observed changes in head circumf...

Using mobile RNAs to improve Nitrogen a...

AtCDF3 gene induced greater production of sugars a...

El diagnóstico genético neonatal mejor...

Un estudio con datos de los últimos 35 años, ind...

Highlight

Eosinófilos. ¿Qué significa tener val...

by Labo'Life

​En nuestro post hablamos sobre este interesante tipo de célula del...

A dietary supplement has beneficial effe...

by Institute for Advanced Chemistry of Catalonia (IQAC-CSIC)

Research led by IIBB-CSIC and CIBEREHD scientists identifies S-adenosy...

Photos Stream